International Journal of Laboratory Hematology

Volume 44, Issue 5 pp. e211-e214

LETTER TO THE EDITOR

Anaemia during venetoclax ramp-up phase: Do not forget unusual causes

Chiara Adele Cavarretta,

Chiara Adele Cavarretta

orcid.org/0000-0002-5757-5687

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Andrea Visentin,

Andrea Visentin

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Stefano Pravato,

Stefano Pravato

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Elisa Piva,

Elisa Piva

Laboratory Medicine, Department of Medicine, University of Padova, Padova, Italy

Search for more papers by this author

Francesco Piazza,

Francesco Piazza

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Daniela Basso,

Daniela Basso

Laboratory Medicine, Department of Medicine, University of Padova, Padova, Italy

Search for more papers by this author

Livio Trentin,

Corresponding Author

Livio Trentin

[email protected]

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Correspondence

Livio Trentin, Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2 35128, Padova, Italy.

Email: [email protected]

Search for more papers by this author

Chiara Adele Cavarretta,

Chiara Adele Cavarretta

orcid.org/0000-0002-5757-5687

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Andrea Visentin,

Andrea Visentin

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Stefano Pravato,

Stefano Pravato

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Elisa Piva,

Elisa Piva

Laboratory Medicine, Department of Medicine, University of Padova, Padova, Italy

Search for more papers by this author

Francesco Piazza,

Francesco Piazza

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Search for more papers by this author

Daniela Basso,

Daniela Basso

Laboratory Medicine, Department of Medicine, University of Padova, Padova, Italy

Search for more papers by this author

Livio Trentin,

Corresponding Author

Livio Trentin

[email protected]

Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

Correspondence

Livio Trentin, Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Via Giustiniani, 2 35128, Padova, Italy.

Email: [email protected]

Search for more papers by this author

First published: 11 May 2022

https://doi.org/10.1111/ijlh.13875

Citations: 1

[Correction added on 30 June 2022, after first online publication: the corresponding author has been changed in this version.]

Chiara Adele Cavarretta and Andrea Visentin contributed equally to the work.

Funding information: Ricerca per Credere nella Vita; Associazione Italiana per la Ricerca sul Cancro

Share a link

Email
Wechat
Bluesky

Open Research

DATA AVAILABILITY STATEMENT

Data available on request from the authors.

REFERENCES

1Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12): 1107-1120. doi:10.1056/NEJMoa1713976
10.1056/NEJMoa1713976
CAS PubMed Web of Science® Google Scholar
2Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019; 380(23): 2225-2236. doi:10.1056/NEJMoa1815281
10.1056/NEJMoa1815281
CAS PubMed Web of Science® Google Scholar
3Jones GL, Will A, Jackson GH, Webb NJ, Rule S, British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015; 169: 661-671. doi:10.1111/bjh.13403
10.1111/bjh.13403
PubMed Web of Science® Google Scholar
4Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62(3): 481-492. doi:10.1053/j.ajkd.2013.02.378
10.1053/j.ajkd.2013.02.378
CAS PubMed Web of Science® Google Scholar
5Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014; 89: 1055-1062. doi:10.1002/ajh.23785
10.1002/ajh.23785
CAS PubMed Web of Science® Google Scholar
6Vitale C, Salvetti C, Griggio V, et al. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood. 2021; 137(25): 3507-3517. doi:10.1182/blood.2020008201
10.1182/blood.2020008201
CAS PubMed Web of Science® Google Scholar
7Nguyen AP, Ness GL. Hemolytic anemia following Rasburicase administration: a review of published reports. J Pediatr Pharmacol Ther 1. 2014; 19(4): 310-316. doi:10.5863/1551-6776-19.4.310
10.5863/1551?6776?19.4.310
PubMed Google Scholar
8Cheah CY, Lew TE, Seymour JF, Burbury K. Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency. Acta Haematol. 2013; 130: 254-259. doi:10.1159/000351048
10.1159/000351048
PubMed Web of Science® Google Scholar
9Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. 2020; 41:100648. doi:10.1016/j.blre.2019.100648
10.1016/j.blre.2019.100648
PubMed Web of Science® Google Scholar
10Noto A, Cassin R, Mattiello V, Reda G. The role of novel agents in treating CLL-associated autoimmune hemolytic anemia. J Clin Med. 2021; 10(10):2064. doi:10.3390/jcm10102064
10.3390/jcm10102064
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume44, Issue5

October 2022

Pages e211-e214

Anaemia during venetoclax ramp-up phase: Do not forget unusual causes

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Anaemia during venetoclax ramp-up phase: Do not forget unusual causes

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Related

Information